

US PATENT & TRADEMARK OFFICE

PATENT APPLICATION FULL TEXT AND IMAGE DATABASE

[Help](#)[Home](#)[Boolean](#)[Manual](#)[Number](#)[PTDLs](#)[Next List](#)[Bottom](#)[View Shopping Cart](#)

Searching PGPUB Production Database March 15th - September 30th 2001...

Results of Search in PGPUB Production Database March 15th - September 30th 2001 for:

AN/"Daiichi Sankyo Company, Limited": 415 applications.

Hits 1 through 50 out of 415

PUB. APP. NO.	Title
1	20200385486 METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE
2	20200385422 METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE
3	20200384121 NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE
4	20200377573 PEPTIDE FOR TREATING AGE-RELATED MACULAR DEGENERATION
5	20200362033 ANTI-CD147 ANTIBODY
6	20200362032 ANTI-GPR20 ANTIBODY AND ANTI-GPR20 ANTIBODY-DRUG CONJUGATE
7	20200352964 OPHTHALMIC AQUEOUS COMPOSITION
8	20200347030 COMPOUND HAVING CYCLIC STRUCTURE
9	20200330415 DRUG FOR RETINAL DEGENERATIVE DISEASE ASSOCIATED WITH PHOTORECEPTOR DEGENERATION
10	20200282073 ANTIBODY-DRUG CONJUGATE
11	20200262917 COMPOSITION FOR CYTOTOXIC T CELL DEPLETION
12	20200261594 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
13	20200239425 GRISEOFULVIN COMPOUND
14	20200231654 ACTIVE MMP9-BINDING PEPTIDE
15	20200216433 GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF
16	20200207837 PEPTIDES INHIBITING KLK1, KLK4, OR KLK4 AND KLK8
17	20200199179 PEPTIDE LIBRARY AND USE THEREOF
18	20200173999 METHOD FOR SELECTING INDIVIDUALS TO BE ADMINISTERED IMMUNE CHECKPOINT INHIBITOR
19	20200172494 PYRIMIDINE DERIVATIVE
20	20200171163 ANTI-CDH6 ANTIBODY AND ANTI-CDH6 ANTIBODY-DRUG CONJUGATE
21	20200131230 THROMBOSPONDIN 1-BINDING PEPTIDE
22	20200123253 ANTIBODY FOR TREATING AUTOIMMUNE DISEASES

- 23 [20200115446 PEDIATRIC OSTEOPOROSIS DRUG THAT DOES NOT CAUSE GROWTH DISORDER](#)
- 24 [20200113842 TABLET](#)
- 25 [20200087321 SULFONAMIDE COMPOUNDS](#)
- 26 [20200085946 MONOCLONAL ANTIBODIES TO HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 2 \(HFGFR2\) AND METHODS OF USE THEREOF](#)
- 27 [20200080080 THERAPEUTIC DRUG FOR ALPORT'S SYNDROME](#)
- 28 [20200062765 Method for Producing 3, 6-Disubstituted Imidazo\[1, 2-b\]Pyridazine Derivative](#)
- 29 [20200061031 METHOD FOR TREATING EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER BY ADMINISTRATION OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE](#)
- 30 [20200040019 N-PHOSPHONOXYMETHYL PRODRUGS OF HYDROXYALKYL THIADIAZOLE DERIVATIVES](#)
- 31 [20200039974 PYRIDINE COMPOUND](#)
- 32 [20200030414 THERAPEUTIC AGENT FOR SHORT STATURE](#)
- 33 [20200017583 ANTI-GPR20 ANTIBODY](#)
- 34 [20200017439 UREA DERIVATIVE](#)
- 35 [20200002427 ANTI-ALK2 ANTIBODY](#)
- 36 [20200002302 GRISEOFULVIN COMPOUND](#)
- 37 [20190376146 METHOD FOR PREDICTING SENSITIVITY OF CANCER TO TREATMENT WITH PD-1 IMMUNE CHECKPOINT INHIBITOR](#)
- 38 [20190367612 ANTI-GPRC5D ANTIBODY AND MOLECULE CONTAINING SAME](#)
- 39 [20190365688 AMIDE DERIVATIVE](#)
- 40 [20190359712 ANTI-CD3 ANTIBODY AND MOLECULES COMPRISING THE ANTIBODY](#)
- 41 [20190345515 DNA ELEMENT HAVING THE ACTIVITY OF ENHANCING FOREIGN GENE EXPRESSION](#)
- 42 [20190343816 PHARMACEUTICAL COMPOSITION USED FOR TREATMENT OF HTLV-1-ASSOCIATED MYELOPATHY](#)
- 43 [20190330368 THERAPY FOR DRUG-RESISTANT CANCER BY ADMINISTRATION OF ANTI-HER2 ANTIBODY/DRUG CONJUGATE](#)
- 44 [20190322740 Anti-Orai1 Antibody](#)
- 45 [20190314362 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND IMMUNE CHECKPOINT INHIBITOR](#)
- 46 [20190309028 NOVEL ENDO-BETA-N-ACETYLGLUCOSAMINIDASE](#)
- 47 [20190284198 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON](#)
- 48 [20190241907 Promoter of Hspa5 Gene](#)
- 49 [20190233466 SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF EYE DISEASE](#)
- 50 [20190225686 ANTI-GPR20 ANTIBODY AND ANTI-GPR20 ANTIBODY-DRUG CONJUGATE](#)